Feedback (FDBK) AI Stock Analysis

3 Followers

Feedback

(LSE:FDBK)

Select Model

Rating:38Underperform

Price Target:GBX 3.50▼(-1.41% Downside)

Action:reiterated

Date:11/10/26

Feedback's exceptionally low score is driven by severe fundamental distress, primarily massive cash burn, collapsing revenue, and highly negative margins. Despite operating debt-free, extreme technical downtrends and a loss-making valuation profile present substantial ongoing risks for investors.

Positive Factors

Debt-free balance sheetThe absence of reported debt limits interest and refinancing burdens, preserving financial flexibility while the company develops its healthcare software. This gives management more room to allocate resources toward operations and product development without debt servicing further increasing cash pressure.

Negative Factors

Shrinking revenueConsecutive revenue declines indicate that the current business has not yet established a dependable growth trajectory. Shrinking scale makes it harder to absorb fixed operating costs, limits reinvestment capacity, and increases the challenge of converting the platform’s healthcare use case into sustainable expansion.

Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: GBP 1.56M
Dividend Yield: ―
Average Volume (3M): 95.21K
Price to Earnings (P/E): -0.4
Beta (1Y): 0.65
Revenue Growth: -11.91%
EPS Growth: 69.57%
Country: UK
Employees: 29
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

Feedback Business Overview & Revenue Model

Company Description

Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio inc...

Feedback Financial Statement Overview

Summary

Financial performance is severely compromised by massive cash burn, shrinking revenues, and deeply negative profit margins (-447%). While a debt-free structure prevents immediate insolvency, rapid equity depletion poses a critical going-concern risk.

Income Statement

12Very Negative

Balance Sheet

45Neutral

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	May 2025	May 2024	May 2023	May 2022	May 2021
Income Statement
Total Revenue	780.14K	780.14K	885.62K	1.18M	1.02M	588.58K
Gross Profit	355.77K	355.77K	778.65K	1.10M	131.39K	-63.68K
EBITDA	-3.18M	-3.13M	-3.06M	-2.73M	-2.61M	-1.96M
Net Income	-3.49M	-3.49M	-7.32M	-3.30M	-2.92M	-2.12M
Balance Sheet
Total Assets	3.42M	3.42M	6.75M	8.34M	11.72M	14.30M
Cash, Cash Equivalents and Short-Term Investments	2.73M	2.73M	5.95M	3.88M	7.32M	10.31M
Total Debt	0	0	0	0	0	0
Total Liabilities	663.97K	663.97K	589.02K	694.18K	855.45K	594.13K
Stockholders Equity	2.75M	2.75M	6.16M	7.64M	10.87M	13.71M
Cash Flow
Free Cash Flow	-2.79M	-2.79M	-2.83M	-2.14M	-2.99M	-2.41M
Operating Cash Flow	-2.79M	-2.79M	-2.82M	-2.22M	-1.74M	-1.25M
Investing Cash Flow	-429.54K	-429.54K	-716.00K	-1.22M	-1.24M	-1.15M
Financing Cash Flow	0	0	5.61M	0	-830	10.49M

Feedback Technical Analysis

Technical Analysis SentimentNegative

Last Price3.55

Price Trends

50DMA6.09Negative

100DMA6.28Negative

200DMA8.53Negative

Market Momentum

MACD-0.73Positive

RSI14.06Positive

STOCH3.17Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Negative. The current price of 3.55 is below the 20-day moving average (MA) of 5.42, below the 50-day MA of 6.09, and below the 200-day MA of 8.53, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 14.06 is Positive, neither overbought nor oversold. The STOCH value of 3.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FDBK.

Feedback Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:FDBK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:KOO	68Neutral	GBP 67.37M	11.22	17.74%	―	-6.51%	108.62%
GB:IXI	55Neutral	GBP 28.47M	-6.50	-16.18%	―	13.04%	15.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:GDR	49Neutral	GBP 14.45M	-0.82	-1044.57%	―	65.60%	74.84%
GB:COG	41Neutral	GBP 15.65M	-9.63	-54.17%	―	11.86%	23.81%
GB:OBD	40Underperform	GBP 16.13M	-0.29	-451.74%	―	33.37%	86.41%
GB:FDBK	38Underperform	GBP 1.56M	-0.45	-96.66%	―	-11.91%	69.57%

* Healthcare Sector Average

Performance Comparison

GB:FDBK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:FDBK	Feedback plc	3.55	-5.05	-58.72%
GB:COG	Cambridge Cognition Holdings	29.00	-4.00	-12.12%
GB:GDR	Genedrive plc	0.90	0.11	13.92%
GB:IXI	IXICO plc	12.75	1.50	13.33%
GB:OBD	Oxford BioDynamics	0.12	-0.17	-58.93%
GB:KOO	Kooth Plc	185.00	57.50	45.10%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Feedback AI Stock Analysis